Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479080 | 0.88 | HTR6 (0.58) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL4483174 | 0.85 | HTR6 (0.48) | HTR6HTR1AHTR7 | |
| SCHEMBL4492526 | 0.84 | HTR6 (0.61) | HTR6HTR1ADRD2HTR7 | |
| SCHEMBL3949533 | 0.81 | HTR6 (0.62) | HTR6HTR1ADRD2HTR7 | |
| SCHEMBL4494776 | 0.80 | HTR6 (0.58) | HTR6 | |
| SCHEMBL3957575 | 0.79 | HTR6 (0.59) | HTR6 | |
| SCHEMBL3954300 | 0.79 | HTR6 (0.53) | HTR6HTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL3949846 | 0.78 | HTR6 (0.58) | HTR6 | |
| SCHEMBL3951523 | 0.78 | HTR6 (0.58) | HTR6HTR1ADRD2HTR7 | |
| SCHEMBL4478040 | 0.78 | HTR6 (0.50) | HTR6HTR1ADRD2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576087-B2 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-08-18 | — | — | US | claimed |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-01-17 | — | — | US | claimed |
| JP-2006517966-A | — | — | 2006-08-03 | — | — | JP | claimed |
| EP-1592690-A1 | HETEROCYCLYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004074286-A1 | HETEROCYCLYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | claimed |
| US-7576087-B2 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-01-17 | — | — | US | disclosed |
| US-7259165-B2 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885HTR1A 6/4885DRD2 120/4885 |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885HTR1A 6/4885DRD2 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.